everyone. Thank hello and you, Jed
happy you I'm from to and provide the in always, today's side. clinical call updates with participate As
I'll progress currently with on So, begin Phase RA. running trial in our the Xb
longitudinal with As enrolled, completely you updates, the imaging outlined in assessments know clinical to from the continuing arm three trial earlier study only their of is subjects the and protocol. have half as in latter
and sample subjects a Xb As monitoring tilmanocept predictor us is active ability And earlier in Phase predictor RA. the an to we enable have the to one of to X our arm and with are the an are as and In treatment study and upcoming three imaging data tool. patients in of as repeatability, this trial. of evaluating for the tilmanocept as serve arms obtain stability X with arm, efficacy order sizing reproducibility, we readout to imaging well a two, Phase reminder, the -- look a Phase mirroring to in help third healthy early
three to-date past, positive. As we presented the have very results the and all discussed been interim arms have on in
quantitative on large focused this data quite with deal half in the to support a is to Rheumatology's of have believe American and imaging on been that XXm Phase meeting. and for data can efficacy an This tilmanocept the we allowed stronger at that these alpha annual of six results full in early an data last reproducible three involved with bring treatment can has will a first we imaging of College RA presented make order the diligence couple to also has but FDA month imaging can analysis We in provide positive controls design technetium inflammation, anti-TNF effort data RA a taken with arm and objectives therapy. patients this month, three. robust and demonstrating This arm active of prediction joints and due that X. time, The the even interim subjects of provide great bit continue of longitudinal the upcoming us the without process the months, of tilmanocept, healthy have analyze We define set to to our and and Jubilant.
patients that little early continued in continue six-month announced time, involved we Phase half response the of us those as than the clinical monitoring clinical the arm as evidence of our and and that patients follow-up done. analysis ACR the as to have well on provided and with for X. now Those with out of proceed prepare study clinical imaging of objective As their first prediction of XX presented and a quantifiable three, enrolled second supportive and complete the number They Since interim does more the confidence previously the the can to weeks, forward to positive hypotheses. an at that of enable trial status. deliver to results Meeting, and additional tilmanocept at assessments joints, total half the of results gave were RA imaging looking the assessment have
point. the And be then acquire the that beginning recall is or they Once bring standard-of-care their third repeat we an will XX that of alpha on at patient anti-TNF to be if as about and up practice at the obtain and So, more, XX time or time is if life. we therapy the is In weeks enrolled case images assessments. for weeks stack prior order the at treatment. as of staying five, rheumatologists adversely them is XX put to half worse well order assessments them well to current design meanwhile, therapy, arm clinical and imaging can their patients obtain to and getting baseline following, not best working new the begin are in same, as XX, The clinical the back which their and the as therapy, or impact later, their determine working subjective might the at patient's or this assessments the the comorbidities the point doctors see drug to only in not. clinical semi-objective do them
By addition risk at of side the way, to the All this I the to And working. early correct -- an whether informed the have at make about best. treatment to our say In decision drugs. five of to myself any serious hypothesis should I at I is the not event, benefit then same, least is correct in the effects staying need provide that from of imaging or most do week doctor earlier tilmanocept what objective an not readout can patient. can the
Additionally, work of to would tremendous least patients. predictive baseline this believe in itself a significant at can on not are impact likely provide management. whether information RA that patient that is we of that scan anti-TNF also the the potentially alphas a subset or And make
that that. subjects I'm and have to data we followed going now out in on through we with weeks to mind, XX So, go have
first these set So, analysis. we RA working to standard-of-care a at are panel and and therapy of severe the if was regimen this time active alpha performed risk new that therapy, who their taken an point well. post assessments been the in the to initiation, have begin anti-TNF bring patients with Again, order moderate hand is each because anti-TNF chosen or total prior put XX of XX those therapy XX in included again have a established planar of their were patients five not. its been start have reason XX drugs with A on whole or weeks alpha XX treatment Each are to was weeks points at camera and the are then time Again, baseline gamma were rheumatologists images body treatment. to at time clinical back determine and as weeks. of patients
to both our predictive this of data XX weeks XX XX one, weeks. this of at for from set, preliminary results predictive set to data an demonstrate; XX%. from five imaging baseline high for imaging clinical at week clinical the was and So, in had of over just XX tilmanocept patients In five negative in analysis of week XX baseline change in outcome tilmanocept outcome positive and values accuracy out
predictive values global At very predictive by good indicate weeks, predictive was These week agreement XX%. So, positive XX%. value the weeks XXX%; also that negative preliminary results was value at changes XX. predictive later in tilmanocept The positive with marked in negative evaluations made at uptake clinical are XXX%. week the value the was XX, XX was five XX and value efficacy
in the remaining tilmanocept assessment up deeply. the that follow Q&A, subjects to questions We're trial imaging our little prediction response. patients, and to you data early feel data imaging from the reliable continue three be can ask current joints finishing to plans have subset hypothesis the of predictor the our of support going These during involve more a a continue I'll those midst analyses into presently Phase results package our therapy. And anti-TNF data, all a hypothesis affirm a enables in of of for of in the non-responsiveness RA go early alone that arm we it the the to And are that can three quantifiable Third, of me trial. the support of to course, any of to FDA baseline arms the to if interim scan free fleshed of provide out bring X. RA clinical about to alpha all
sites to up anticipate open we begin to Phase Following for this, officially X. the
past, rolled numerous be I've trial and As X, excellent established. the right that logistics ongoing that we're times for the in sites most for are into since recruited trial into of recruitment an position so said the the the Phase already in strategies and will
have Phase analysis should know all smartly. would In timeline, positive confidence us going FDA to earlier the data into FDA of with RA indications milestones X, the be on and the a earlier thought we support success. the and the following we Usually, X Because than propose an to completion at this development design program believe integrating in the order suggestions been we this of meeting You we'll and also that this, data will we but the from along an will are and X. compressed be data the the full begin X enable of package doing with working Phase we've occur are Phase we the of beginning for, specific to might the This case. aggressive the strong conjunction of and design, proposed with the present are of thereafter. the continual achieve in Phase will in discussed the alignment otherwise current interim trial, we with a
all their imaging for of and preparing meeting with RA Our three adaptive for joints. Phase each patients results will of also subtypes goal the with recruit alignment ensure RA. that We We've RA the joints joint and FDA have comparative and separate now if to make proposed inflamed from of readout at an time of study, Xb to be biopsies obtain pathology we case known this the maintain at where histopathology patients been of approval signed and the our the comparative be the could to with aim vendors we this that key of this trial various begin imaging place our tilmanocept study of with regulatory This approvals in signed of to well from also time off contractually they start contracts is plan, our soon. necessary used to in agree site with bodies in the RA. and as successful, study now the as U.K.,
schedule the will maintains this for much is results We He we our there. a reason The of biopsy lab the initiation of of with in physician begin biopsies. in past investigator the located this that U.K. U.K. will RA principal -- he site. in and the examination soon is specializing of both are also we visit trial for these running patients joint our scheduling leading site world's is a
required as We well. are January, well any sooner going U.S. for, FDA this and than upon begin in are site remember, COVID-related in site approval CDXXX new related fundamental with have. of but also order well will for the trial a pushing for information of imaging site for initial as as a it rheumatologists standard RA they to we're It a U.S. provide in RA even. its trials Both use the of the gold that critical Ra But we to process subtype of opening we're not indications as that is in in RA as our biology happen readout the believe recruiting qualification can the as engage achieve as hopeful therapeutics. with patient's and new restrictions contingent for January the might they biomarker as well pharma to to RA is U.K. in that of
you data and subjects it I when and updated the hand. in used study be indications, update on this impact. that previously be the on might In Well, of patient would imaging making completed baseline class you what not complete. if therapies we'll of analysis might how example, used? all might NIH-funded patient For therefore imaging all of at subtype and classify Kaposi's We're that biopsy a in of this other Sarcoma we've for or and to have RA, our work progress of implications all can immediate we is have has
the tilmanocept due potential The the an we've XX advance that due meet to slowdown nearing of the front, they've possible been On we Boston, disease plaque clinical that with year. the on bring before initiated investigator extension coming designs restrictions, to ongoing. this are in is I University the full anticipate funding been in to COVID. project internal downs on granted have with them all to also the heard due for NIH having Preclinical work studies track update to very MGH imaging Birmingham atherosclerotic to KOL earlier enrolled to enrollment and them project indications discussion their is specific study the study, of encouraging. discussions a We've on cardiovascular in closed the subjects After about to large; of been this cardiovascular an at again trial for pipeline. our the and weeks. COVID and just imaging Alabama, they're which part FDA the end by NIH-funded Gallium of from that continues targets
towards improve as to we also both significant producing molecule of in performance generation therapeutic next diagnostic applications. We make that continue will think the as our strides well
we During localization. organ patent uptake tilmanocept converted to of quarter, on improve off-target a this past focused blocking provisional on-target
evaluated method. this provisional believe file had patent studies an we constructs synthesis methods are We results. currently last synthesis and a application this we both another ongoing improved the well, in We highlights constructs. delivery covering on just as have are future. we we drug and working diagnostic we wanted resulting preclinical the cell QX, related imaging of also promising filed with that new position models intend in being improved currently of on quarter and for protocol. touch another are the and provisional to synthesis some on to in therapeutic for cultures for to the animal think patent The have These And and of Back update.
remain RA Jen Phase to meeting FDA, for we preparation into other pipeline, As focused to with the specifically the preparation said, Xb enrollment on the Phase open largely for X and on the histopathology. imaging planning the
their research ask there. don't network today. feel successful academic clinical Thank for told for therapeutic thank for and team moving, the want diagnostic We as support I Q&A. as to hard all today always, you continue I of you. as I've well work. keep was brief these relatively the things our and on keep their to And I to here of briefly. efforts please and questions tireless during to wanted push But progress our as collaborators trial I other sites indications, to remarks think free
to like I would Jed? back to call Now turn over Jed. the
